metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P- 78 DIETHYlNITROSAMINE AND 2-ACETYLAMINOFLUORENE CHRONIC ADMINISTRATION LEADS ...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
P- 78 DIETHYlNITROSAMINE AND 2-ACETYLAMINOFLUORENE CHRONIC ADMINISTRATION LEADS TO BIOCHEMICAL, HISTOLOGIC AND GENETIC CHANGES RELATED TO HEPATOCELLULAR CARCINOMA IN WISTAR RATS
Visitas
194
Jaime Sánchez-Meza1, Marina Campos-Valdez1, José Alfredo Domínguez-Rosales1, Saraí Citlalic Rodríguez-Reyes2, Erika Martínez-López2, Juliana Marisol Godínez-Rubí3, Adriana María Salazar-Montes1, Laura Verónica Sánchez-Orozco1
1 Institute of Chronic Degenerative Diseases, Department of Molecular Biology and Genomics, University Center of Health Sciences, University of Guadalajara, Guadalajara Jalisco, Mexico
2 Institute of Nutrigenetics and Translational Nutrigenomics, Department of Molecular Biology and Genomics, University Center of Health Sciences, University of Guadalajara, Guadalajara Jalisco, Mexico
3 Diagnostic Pathology and Immunohistochemistry Laboratory, Department of Microbiology and Pathology, University Center of Health Sciences, University of Guadalajara, Guadalajara Jalisco, Mexico
Este artículo ha recibido
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Hepatocellular carcinoma (HCC) is one of the neoplasms with the highest mortality worldwide. The causes of the development of HCC have been related to hepatitis B virus and exposure to aflatoxin B1; however, chronic alcohol use, nonalcoholic fatty liver disease, and hepatitis C virus infection are the most important risk factors for developing HCC. The establishment of animal models of HCC is crucial for both basic and translational studies of hepatocellular carcinoma and is a valuable tool to identify alterations during the progression of the disease. This study aimed to analyze the biochemical, histological, and gene expression alterations produced in a model of chemical hepatocarcinogenesis by the chronic administration of diethylnitrosamine (DEN) and 2-acetylaminofluorene (2-AAF) in Wistar rats.

Materials and Methods

Twelve Wistar rats weighing 180 to 200 g were divided into control and damage groups: rats were treated with DEN (50 mg/kg/wk) i.p and an intragastric dose of 2-AAF (25 mg/kg/wk) for 18 weeks. Serum clinical biochemistry was performed on VITROS Chemistry System 350® equipment. Masson's trichrome and Hematoxylin-Eosin stains were performed on the liver tissue. Relative gene expression was performed by RT-qPCR in LightCycler®96.

Results

The damage group had significant increases in total cholesterol, HDL-C, AST, ALT, ALKP, and GGT. Furthermore, histological analysis showed the loss of normal liver architecture with nuclear pleomorphism in the hepatocytes, atypical mitosis, and fibrous septa distributed between portal triads and collagen fibers through the hepatic sinusoids. The expression of TGFb1 was significantly increased (p<0.05); on the contrary, ALB, CAT and, PPARα were downregulated (P<0.05), CPT1A was downregulated too but without significance.

Conclusions

Chronic administration of DEN and 2-AAF induces characteristic alterations of hepatocellular carcinoma in Wistar rats. The uncontrolled proliferation of malignant cells requires a constant supply of energy and macromolecules. In this work, cancer cells reprogrammed their fatty acid oxidation pathway by downregulation of PPARα and CPT1A.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos